至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Generation of Gal-enhanced bifunctional tumor vaccine

Acta Pharm Sin B. 2022-03; 
Jian He, Yu Huo, Zhikun Zhang, Yiqun Luo, Xiuli Liu, Qiaoying Chen, Pan Wu, Wei Shi, Tao Wu, Chao Tang, Huixue Wang, Lan Li, Xiyu Liu, Yong Huang, Yongxiang Zhao, Lu Gan, Bing Wang, Liping Zhong
Products/Services Used Details Operation
Custom Vector Construction … MHCC97H cells stably expressing α1,3 GT or/and END and MHCC97H cells stably transduced with empty pLVX-Puro vector were generated using GenScript (Nanjing, China) and … Get A Quote

摘要

Hepatocellular carcinoma (HCC) is a common malignant tumor with poor prognosis and high mortality. In this study, we demonstrated a novel vaccine targeting HCC and tumor neovascular endothelial cells by fusing recombinant MHCC97H cells expressing porcine -1,3-galactose epitopes (Gal) and endorphin extracellular domains (END) with dendritic cells (DCs) from healthy volunteers. END/Gal-MHCC97H/DC fusion cells induced cytotoxic T lymphocytes (CTLs) and secretion of interferon-gamma (IFN-). CTLs targeted cells expressing Gal and END and tumor angiogenesis. The fused cell vaccine can effectively inhibit tumor growth and prolong the survival time of human hepatoma mice, indicating the high clinical potential of this ... More

关键词

Cytotoxic T lymphocytes, Dendritic cells, Endoglin, Fusion cells, Hepatocellular carcinoma, Immunotherapy, Tumor neovascular endothelial cells, αGal